Apyx Medical Expects 2024 Revenues Of $46.6M-$47.6M Compared To Prior Guidance Of $50.6M-$52.1M Versus Consensus Of $50.767M

apyx medical预计2024年收入为4660万美元。与之前的指导5060万美元相比。与50.767亿美元的共识相比5210万美元

Benzinga · 2024/11/08 20:12

The Company is updating its financial guidance for the year ending December 31, 2024 to:

公司正在更新截至2024年12月31日的财务指引：

Total revenue is now expected to be in the range of $46.6 million to $47.6 million, representing a decrease from 2023 of approximately 11% to 9%. The Company's prior guidance range for total revenue was $50.6 million to $52.1 million.
- Total revenue guidance assumes:
  - Revenue from the Advanced Energy segment is now expected to be in the range of $37.2 million to $38.2 million, representing a decrease from 2023 of approximately 14% to 12%. The Company's prior guidance range for Advanced Energy revenue was $41.6 million to $43.1 million.
  - Revenue from the OEM segment is now expected to be approximately $9.4 million, representing growth of approximately 5% from 2023. The Company's prior guidance for OEM revenue was approximately $9.0 million.
Net loss attributable to stockholders is now expected to be approximately $25.0 million, compared to $18.7 million for the year ended December 31, 2023. The Company's prior guidance range for net loss attributable to stockholders was $24.5 million to $23.5 million.

预计总收入现在将在$4660万至$4760万的区间内，较2023年下降约11%至9%。公司此前对总收入的指引区间为$5060万至$5210万。
- 总收入指引假定：
  - Advanced能源部门的营业收入现预计将在$3720万至$3820万的区间内，较2023年下降约14%至12%。公司先前对Advanced能源收入的指引区间为$4160万至$4310万。
  - OEm部门的营业收入现预计将约为$940万，较2023年增长约5%。公司先前对OEm收入的指引约为$900万。
归属股东的净损失现预计约为$2500万，较2023年12月31日年度的$1870万有所增加。公司先前对归属股东的净损失的指引区间为$2450万至$2350万。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

风险及免责提示